Last reviewed · How we verify
NCT05931224
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
Phase 3 trial testing D064, D702, placebo of D660 in Essential Hypertension in 346 participants. Completed in 13 May 2024.
13 May 2024
Quick facts
| Lead sponsor | Chong Kun Dang Pharmaceutical |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 346 |
| Start date | 28 June 2023 |
| Primary completion | 13 May 2024 |
| Estimated completion | 13 May 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- D064, D702, placebo of D660 — full drug profile →
- D660, placebo of D064, placebo of D702 — full drug profile →
Conditions studied
- Essential Hypertension — all drugs for Essential Hypertension →
Sponsor
Chong Kun Dang Pharmaceutical — full company profile →
Who can join
19 and older, any sex, with Essential Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05931224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Essential Hypertension
Currently open trials in the same condition.
- NCT07282145 — Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers · Phase 1 · recruiting
- NCT06778239 — Childhood-Onset Essential Hypertension Natural History Study · recruiting
- NCT07051811 — To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension · NA · recruiting
- NCT06643819 — Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A · Phase 3 · recruiting
- NCT05880056 — Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian P · Phase 4 · recruiting
Other Chong Kun Dang Pharmaceutical trials
Trials by the same sponsor.
- NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
- NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
- NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
- NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05931224 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
- Last refreshed: 4 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05931224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing